Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma - Trial NCT05949944
Access comprehensive clinical trial information for NCT05949944 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Yat-sen University
Timeline & Enrollment
Phase 1/2
Aug 01, 2023
Dec 01, 2026
Primary Outcome
Dose-limiting toxicity (DLT, Phase Ib),Complete remission rate (CR rate) based on the 2014 Lugano evaluation criteria (Phase II)
Summary
This phase Ib/II, single arm, open label, multicenter study is conducted to evaluate the
 efficacy and safety of linperlisib in combination with CHOP for newly diagnosed PTCL
 patients, and explore the reasonable dosage of linperlisib when combined with CHOP regimen.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05949944
Non-Device Trial